<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d441">
    <sentence id="DDI-DrugBank.d441.s0" text="Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase.">
        <entity id="DDI-DrugBank.d441.s0.e0" charOffset="30-38"
            type="drug" text="Linezolid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s1" text="Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.">
        <entity id="DDI-DrugBank.d441.s1.e0" charOffset="11-19"
            type="drug" text="linezolid"/>
        <entity id="DDI-DrugBank.d441.s1.e1" charOffset="60-69"
            type="group" text="adrenergic"/>
        <entity id="DDI-DrugBank.d441.s1.e2" charOffset="75-93"
            type="group" text="serotonergic agents"/>
        <pair id="DDI-DrugBank.d441.s1.p0" e1="DDI-DrugBank.d441.s1.e0"
            e2="DDI-DrugBank.d441.s1.e1" ddi="true" type="int"/>
        <pair id="DDI-DrugBank.d441.s1.p1" e1="DDI-DrugBank.d441.s1.e0"
            e2="DDI-DrugBank.d441.s1.e2" ddi="true" type="int"/>
        <pair id="DDI-DrugBank.d441.s1.p2" e1="DDI-DrugBank.d441.s1.e1"
            e2="DDI-DrugBank.d441.s1.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s2" text="Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.">
        <entity id="DDI-DrugBank.d441.s2.e0" charOffset="0-16"
            type="group" text="Adrenergic Agents"/>
        <entity id="DDI-DrugBank.d441.s2.e1" charOffset="45-49"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s2.e2" charOffset="134-155"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d441.s2.e3" charOffset="158-168"
            type="group" text="vasopressor"/>
        <entity id="DDI-DrugBank.d441.s2.e4" charOffset="173-191"
            type="group" text="dopaminergic agents"/>
        <pair id="DDI-DrugBank.d441.s2.p0" e1="DDI-DrugBank.d441.s2.e0"
            e2="DDI-DrugBank.d441.s2.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s2.p1" e1="DDI-DrugBank.d441.s2.e0"
            e2="DDI-DrugBank.d441.s2.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s2.p2" e1="DDI-DrugBank.d441.s2.e0"
            e2="DDI-DrugBank.d441.s2.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s2.p3" e1="DDI-DrugBank.d441.s2.e0"
            e2="DDI-DrugBank.d441.s2.e4" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s2.p4" e1="DDI-DrugBank.d441.s2.e1"
            e2="DDI-DrugBank.d441.s2.e2" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s2.p5" e1="DDI-DrugBank.d441.s2.e1"
            e2="DDI-DrugBank.d441.s2.e3" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s2.p6" e1="DDI-DrugBank.d441.s2.e1"
            e2="DDI-DrugBank.d441.s2.e4" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s2.p7" e1="DDI-DrugBank.d441.s2.e2"
            e2="DDI-DrugBank.d441.s2.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s2.p8" e1="DDI-DrugBank.d441.s2.e2"
            e2="DDI-DrugBank.d441.s2.e4" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s2.p9" e1="DDI-DrugBank.d441.s2.e3"
            e2="DDI-DrugBank.d441.s2.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s3" text="Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.">
        <entity id="DDI-DrugBank.d441.s3.e0" charOffset="28-46"
            type="drug" text="phenylpropanolamine"/>
        <entity id="DDI-DrugBank.d441.s3.e1" charOffset="52-66"
            type="drug" text="pseudoephedrine"/>
        <pair id="DDI-DrugBank.d441.s3.p0" e1="DDI-DrugBank.d441.s3.e0"
            e2="DDI-DrugBank.d441.s3.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s4" text="Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.">
        <entity id="DDI-DrugBank.d441.s4.e0" charOffset="17-33"
            type="group" text="adrenergic agents"/>
        <entity id="DDI-DrugBank.d441.s4.e1" charOffset="44-51"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d441.s4.e2" charOffset="56-66"
            type="drug" text="epinephrine"/>
        <pair id="DDI-DrugBank.d441.s4.p0" e1="DDI-DrugBank.d441.s4.e0"
            e2="DDI-DrugBank.d441.s4.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s4.p1" e1="DDI-DrugBank.d441.s4.e0"
            e2="DDI-DrugBank.d441.s4.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s4.p2" e1="DDI-DrugBank.d441.s4.e1"
            e2="DDI-DrugBank.d441.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s5" text="Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.">
        <entity id="DDI-DrugBank.d441.s5.e0" charOffset="0-18"
            type="group" text="Serotonergic Agents"/>
        <entity id="DDI-DrugBank.d441.s5.e1" charOffset="42-50"
            type="drug" text="linezolid"/>
        <entity id="DDI-DrugBank.d441.s5.e2" charOffset="56-74"
            type="group" text="serotonergic agents"/>
        <pair id="DDI-DrugBank.d441.s5.p0" e1="DDI-DrugBank.d441.s5.e0"
            e2="DDI-DrugBank.d441.s5.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s5.p1" e1="DDI-DrugBank.d441.s5.e0"
            e2="DDI-DrugBank.d441.s5.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s5.p2" e1="DDI-DrugBank.d441.s5.e1"
            e2="DDI-DrugBank.d441.s5.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s6" text="Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.">
        <entity id="DDI-DrugBank.d441.s6.e0" charOffset="79-83"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s6.e1" charOffset="89-107"
            type="group" text="serotonergic agents"/>
        <entity id="DDI-DrugBank.d441.s6.e2" charOffset="120-134"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d441.s6.e3" charOffset="144-182"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d441.s6.e4" charOffset="185-189"
            type="group" text="SSRIs"/>
        <pair id="DDI-DrugBank.d441.s6.p0" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e1" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s6.p1" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e2" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s6.p2" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e3" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s6.p3" e1="DDI-DrugBank.d441.s6.e0"
            e2="DDI-DrugBank.d441.s6.e4" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d441.s6.p4" e1="DDI-DrugBank.d441.s6.e1"
            e2="DDI-DrugBank.d441.s6.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s6.p5" e1="DDI-DrugBank.d441.s6.e1"
            e2="DDI-DrugBank.d441.s6.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s6.p6" e1="DDI-DrugBank.d441.s6.e1"
            e2="DDI-DrugBank.d441.s6.e4" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s6.p7" e1="DDI-DrugBank.d441.s6.e2"
            e2="DDI-DrugBank.d441.s6.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s6.p8" e1="DDI-DrugBank.d441.s6.e2"
            e2="DDI-DrugBank.d441.s6.e4" ddi="false"/>
        <pair id="DDI-DrugBank.d441.s6.p9" e1="DDI-DrugBank.d441.s6.e3"
            e2="DDI-DrugBank.d441.s6.e4" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s7" text="Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).">
        <entity id="DDI-DrugBank.d441.s7.e0" charOffset="30-34"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s7.e1" charOffset="52-70"
            type="group" text="serotonergic agents"/>
        <pair id="DDI-DrugBank.d441.s7.p0" e1="DDI-DrugBank.d441.s7.e0"
            e2="DDI-DrugBank.d441.s7.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s8" text="If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).">
        <entity id="DDI-DrugBank.d441.s8.e0" charOffset="104-108"
            type="brand" text="ZYVOX"/>
        <entity id="DDI-DrugBank.d441.s8.e1" charOffset="125-143"
            type="group" text="serotonergic agents"/>
        <pair id="DDI-DrugBank.d441.s8.p0" e1="DDI-DrugBank.d441.s8.e0"
            e2="DDI-DrugBank.d441.s8.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d441.s9" text="Drug-Laboratory Test Interactions There are no reported drug-laboratory test interactions."/>
</document>
